Taisho Pharmaceutical Holdings Co (TSE:4581) ROCE % : 1.97% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Taisho Pharmaceutical Holdings Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 1.97%.

Taisho Pharmaceutical Holdings Co ROCE % Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co ROCE % Chart

Taisho Pharmaceutical Holdings Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

8.58

3.83

2.86

2.62

3.50

Taisho Pharmaceutical Holdings Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															5.83	-0.17	3.26	2.65	1.97

Taisho Pharmaceutical Holdings Co ROCE % Calculation

Taisho Pharmaceutical Holdings Co's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	29667	/	( ( (888159 - 62277)	+	(941490 - 73778) )	/ 2 )
	=	29667	/	( (825882	+	867712)	/ 2 )
	=	29667	/	846797
	=	3.50 %

Taisho Pharmaceutical Holdings Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	18196	/	( ( (1000111 - 79600)	+	(1005463 - 80824) )	/ 2 )
	=	18196	/	( ( 920511	+	924639 )	/ 2 )
	=	18196	/	922575
	=	1.97 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Taisho Pharmaceutical Holdings Co (TSE:4581) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Taisho Pharmaceutical Holdings Co ROCE % Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TAIPY:USA TAISF:USA

Address

3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655

Website

http://www.taisho-holdings.co.jp

Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines